



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:54
Last Report Issued 02/02/2012 08:16

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1275SP
Patient ID 1275SP
Chain 12000241
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 12000241
Received 02/02/2012 08:13

Sample ID 12000241-001
Matrix Serum or Plasma
Patient Name 1275SP
Patient ID 1275SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

1275SP Clonidine, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Clonidine	None Detected	ng/mL	0.050	
-----------	---------------	-------	-------	--

Synonym(s): Kapvay®; Duraclon; Catapres®
Immediate-release, oral: 0.50 - 2.0 ng/mL, 2 hours after administration
Sustained-release, patch: 0.20 - 2.0 ng/mL, at steady-state
Sustained-release, oral: 0.20 - 0.27 ng/mL, 6.8 +/- 3.6 hours after a 0.1 mg single dose in healthy fed adults;
children receive higher doses on a mg/kg basis.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.